| Literature DB >> 27660322 |
Cynthia L Gong1, Joel W Hay1, Daniella Meeker2, Jason N Doctor1.
Abstract
OBJECTIVE: To elicit prescribers' preferences for behavioural economics interventions designed to reduce inappropriate antibiotic prescribing, and compare these to actual behaviour.Entities:
Keywords: antibiotic prescribing; conjoint analysis; discrete choice; revealed preference; stated preference
Year: 2016 PMID: 27660322 PMCID: PMC5051402 DOI: 10.1136/bmjopen-2016-012739
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Attributes and descriptions
| Attribute | Description |
|---|---|
| SA | If you enter a target ARI diagnosis into the patient electronic health record, the EHR will prominently display a list of appropriate non-antibiotic prescription and non-prescription treatment alternatives to antibiotics |
| JA | If you order an antibiotic for a patient with an ARI, a new EHR screen will pop up that asks you to enter a short written justification for why the antibiotic prescription was necessary. What you write in this screen becomes part of the patient's permanent medical record, and therefore visible to other providers |
| PC | Each other week, you and your peers will receive in your work mailboxes (or email) an updated ranking comparing your antibiotic prescribing rate to the top-performing (ie, ‘best’) decile of your clinical peers |
| P4P | If you are able to reduce your rate of antibiotic prescribing for all of your patients with ARI to the lowest 10th centile of your peers, you will receive a predetermined monthly reward payment of either $100 or $200 |
| AT | Your productivity management record system will change the RVU/visit time allowed for each patient with ARI to increase by 5 min per visit as you respond to the patient's concerns regarding the alternative treatments for their ARI diagnosis. If you achieve the antibiotic prescription reduction goal of reducing your antibiotic prescriptions by 50%, this 5 min per visit time will be preserved |
ARI, acute respiratory tract infection; AT, additional time; EHR, Electronic Health Record; JA, Accountable Justifications; P4P, pay-for-performance; PC, Peer Comparison; RVU, relative value units; SA, Suggested Alternatives.
Figure 1DCE treatment scenarios. DCE, discrete choice experiment.
Baseline demographics
| Total (n=234) | Control (n=24) | Treatment (n=210) | |
|---|---|---|---|
| Characteristics | Number (%) | Number (%) | Number (%) |
| Age (years, mean) | 48.5 | 47.8 | 48.6 |
| Gender | |||
| Female | 137 (58.5%) | 12 (50.0%) | 125 (59.5%) |
| Male | 81 (34.6%) | 11 (45.8%) | 70 (33.3%) |
| No response | 16 (6.8%) | 1 (4.2%) | 15 (7.1%) |
| Years of practice (mean) | 19.9 | 19.0 | 21.2 |
| Professional credentials | |||
| Medical doctor | 174 (74.4%) | 18 (75.0%) | 156 (74.3%) |
| Nurse practitioner | 24 (10.3%) | 2 (8.3%) | 22 (10.5%) |
| Physician assistant | 13 (5.6%) | 2 (8.3%) | 11 (5.2%) |
| Doctor of osteopathy | 6 (2.6%) | 1 (4.2%) | 5 (2.4%) |
| No response | 17 (7.3%) | 1 (4.2%) | 16 (7.6%) |
| Specialty | |||
| Internal medicine | 126 (53.5%) | 14 (58.3%) | 112 (53.3%) |
| Paediatrics | 23 (9.8%) | 2 (8.3%) | 21 (10%) |
| Family/general practice | 28 (12.0%) | 3 (12.5%) | 25 (11.9%) |
| Geriatrics | 3 (1.3%) | 0 | 3 (1.3%) |
| Rheumatology | 1 (0.43%) | 0 | 1 (0.43%) |
| Preventive medicine | 1 (0.43%) | 0 | 1 (0.43%) |
| Infectious disease | 1 (0.43%) | 0 | 1 (0.43%) |
| Midwife | 1 (0.43%) | 0 | 1 (0.43%) |
| No response/other | 50 (21.4%) | 5 (20.8%) | 45 (21.4%) |
BEARI study mixed logit regression results
| Exposure group | OR (95% CI) | Coefficient | SE (95% CI) | p Value | p Value* |
|---|---|---|---|---|---|
| Full sample (n=239) | <0.001 | ||||
| Pay-for-performance | 1.007 (1.006 to 1.008) | 0.007 | 0.001 (0.006 to 0.008) | 0.000 | |
| SA | 2.108 (1.727 to 2.573) | 0.746 | 0.102 (0.546 to 0.945) | 0.000 | |
| JA | 1.092 (0.85 to 1.404) | 0.088 | 0.128 (−0.162 to 0.339) | 0.490 | |
| PC | 1.446 (1.184 to 1.766) | 0.369 | 0.102 (0.169 to 0.568) | 0.000 | |
| Additional time | 1.159 (1.105 to 1.216) | 0.147 | 0.024 (0.1 to 0.195) | 0.000 | |
| Controls (n=24) | 0.414 | ||||
| Pay-for-performance | 1.006 (1.003 to 1.009) | 0.006 | 0.002 (0.003 to 0.009) | 0.000 | |
| SA | 2.074 (1.302 to 3.303) | 0.729 | 0.237 (0.264 to 1.195) | 0.002 | |
| JA | 0.924 (0.512 to 1.67) | −0.079 | 0.302 (−0.67 to 0.513) | 0.794 | |
| PC | 1.563 (1.01 to 2.421) | 0.447 | 0.223 (0.01 to 0.884) | 0.045 | |
| Additional time | 1.085 (0.99 to 1.191) | 0.082 | 0.047 (-0.01 to 0.174) | 0.082 | |
| SA (n=135) | <0.001 | ||||
| Pay-for-performance | 1.007 (1.006 to 1.009) | 0.007 | 0.001 (0.006 to 0.009) | 0.000 | |
| SA | 2.199 (1.626 to 2.973) | 0.788 | 0.154 (0.486 to 1.09) | 0.000 | |
| JA | 1.009 (0.719 to 1.418) | 0.009 | 0.173 (-0.33 to 0.349) | 0.957 | |
| PC | 1.552 (1.173 to 2.054) | 0.440 | 0.143 (0.159 to 0.72) | 0.002 | |
| Additional time | 1.192 (1.117 to 1.274) | 0.176 | 0.034 (0.11 to 0.242) | 0.000 | |
| JA (n=121) | <0.001 | ||||
| Pay-for-performance | 1.006 (1.005 to 1.008) | 0.006 | 0.001 (0.005 to 0.008) | 0.000 | |
| SA | 1.955 (1.504 to 2.54) | 0.670 | 0.134 (0.408 to 0.932) | 0.000 | |
| JA | 1.451 (1.061 to 1.984) | 0.372 | 0.160 (0.059 to 0.685) | 0.020 | |
| PC | 1.429 (1.097 to 1.861) | 0.357 | 0.135 (0.093 to 0.621) | 0.008 | |
| Additional time | 1.174 (1.095 to 1.259) | 0.160 | 0.036 (0.09 to 0.23) | 0.000 | |
| PC (n=101) | <0.001 | ||||
| Pay-for-performance | 1.007 (1.005 to 1.009) | 0.007 | 0.001 (0.005 to 0.009) | 0.000 | |
| SA | 2.589 (1.819 to 3.685) | 0.951 | 0.180 (0.598 to 1.304) | 0.000 | |
| JA | 1.079 (0.684 to 1.703) | 0.076 | 0.233 (−0.38 to 0.532) | 0.744 | |
| PC | 1.285 (0.901 to 1.832) | 0.250 | 0.181 (−0.105 to 0.605) | 0.167 | |
| Additional time | 1.200 (1.103 to 1.305) | 0.182 | 0.043 (0.098 to 0.266) | 0.000 | |
Results indicate the OR of each alternative relative to the control group, broken down by exposure group (full sample, controls, SA, JA and PC).
*p Value for significance across all coefficients for that sample.
BEARI, use of behavioral economics and social psychology to improve treatment of acute respiratory infections; JA, Accountable Justifications; PC, Peer Comparison; SA, Suggested Alternatives.
WTP estimates
| WTP | Monthly | Annually |
|---|---|---|
| Controls | ||
| SA | −$120.52 | −$1446.28 |
| JA | $12.98 | $155.81 |
| PC | −$73.84 | −$886.09 |
| Additional time | −$13.55 | −$162.61 |
| SA | ||
| SA | −$108.21 | −$1298.56 |
| JA | −$1.29 | −$15.48 |
| PC | −$60.38 | −$724.56 |
| Additional time | −$24.17 | −$290.04 |
| JA | ||
| SA | −$109.21 | −$1310.46 |
| JA | −$60.65 | −$727.81 |
| PC | −$58.16 | −$697.90 |
| Additional time | −$26.10 | −$313.23 |
| PC | ||
| SA | −$129.43 | −$1553.13 |
| JA | −$10.34 | −$124.06 |
| PC | −$34.07 | −$408.80 |
| Additional time | −$24.79 | −$297.43 |
Negative values indicate the value of that particular alternative to the prescriber; thus, the absolute value is the amount the prescriber is willing to accept; a positive number implies that the prescriber would be willing to give up that dollar amount rather than use the alternative presented.
JA, Accountable Justifications; PC, Peer Comparison; SA, Suggested Alternatives; WTP, willingness-to-pay.